Laboratory of Systems Integration Pharmacology, Clinical & Regulatory Science Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa
Rosa Direito earned her PhD in Pharmacy (Food Science), having been awarded a fellowship by the Dean of the University of Lisbon. She has a background in experimental models of disease, mainly on animal models of acute and chronic inflammation (ulcerative colitis, rheumatoid arthritis) and in vitro model of colon cancer, and how certain fruits, vegetables and herbs can have an impact on inflammatory processes. Her research interests span the crossroads of the brain-gut axis and how diet and the microbiome can have an impact on health. Over the years she has also mentored and collaborated with students from different degrees, is certified in the handling of laboratory animals, and is an instructor of a postgraduate course on laboratory animal sciences. After finishing her PhD, she has sought to contribute to science internationally by becoming an active certified reviewer and has joined the board of reviewers and editorial board of several scientific journals.
EDUCATION
Post-doctoral Fellow (2021-2022), IHMT, Lisboa, Portugal
Post-doctoral Fellow (2020), Instituto Gulbenkian Ciência (IGC), Oeiras, Portugal
PhD (2019) in Pharmacy (Food Science), University of Lisbon, Lisbon, Portugal
MSc (2009) in Biochemistry, University of Coimbra, Coimbra, Portugal
BSc (2005) in Biochemistry, University of Coimbra, Coimbra, Portugal
RESEARCH INTERESTS
Her research interests span the crossroads of the brain-gut axis and how diet and the microbiome can have an impact on health.
Development and Characterization of Mesembryanthemum crystallinum L. Extract-Loaded Phytosomes for Enhanced Delivery of Antioxidant Compounds Irina Fernandes, Ana Iglesias-Mejuto, João M. P. Coelho, Rosa Direito, Catarina P. Reis Life, 2026 M. crystallinum is an edible halophytic succulent plant rich in phenolic compounds with potential pharmaceutical applications. However, it is known that these phytocompounds generally present low absorption, which hinders their direct use in formulations. Therefore, delivery systems, such as phytosomes, can be regarded as a potential strategy to overcome this disadvantage. This study aimed, for the first time, to prepare extracts from the ice plant using different solvents and to incorporate them into phytosomes. Physicochemical characterization of these phytosomes, their antioxidant activity, as well as the quantification and in vitro release profile of their phenolic and flavonoid compounds were studied. Different extraction solvents were assayed, and Ethanol:Acetone (80:20) achieved a strong antioxidant activity (reaching ca. 71.16%), extracting 3200.3 mg of GAE/100 g and 761.7 mg of QE/100 g of phenolic and flavonoid compounds, respectively. The phytosomal formulation exhibited a mean particle size of 233.80 nm, a polydispersity index of 0.23, and a zeta potential of −27.27 mV. Furthermore, a high encapsulation efficiency (96.63%) of the extracts in the phytosomes was obtained. The in vitro release test indicated that the antioxidant activity was retained, reaching a maximum of 42%, accompanied by a release of 51% of the flavonoid content at the end of the 3 h assay, under the experimental conditions. These findings highlight the potential of phytosomes formulated with Mesembryanthemum crystallinum extract as a delivery system for antioxidant phytochemicals.
Bridging the Gut Microbiota and the Brain, Kidney, and Cardiovascular Health: The Role of Probiotics Milena Rosa Lopes, Rosa Direito, Elen Landgraf Guiguer, Vitor Cavallari Strozze Catharin, Tereza Lais Menegucci Zutin, et al. Probiotics and Antimicrobial Proteins, 2026 The symbiosis between intestinal bacteria and the human body’s physiological processes can modulate health. The intestinal microbiota is linked to the development of neurotrophic factors; therefore, it is increasingly related to the modulation of nervous system pathologies. Moreover, microbiota can interfere with inflammation and oxidative stress, which are closely linked to cardiovascular risk factors and several other inflammatory conditions, such as kidney and neurodegenerative diseases. Probiotics are live microorganisms that help regulate and maintain healthy microbiota; thus, they can help prevent these diseases. Due to these reasons, this review aimed to evaluate the effects of probiotics on the gut, kidneys, brain, and heart homeostasis. Clinical trials showed several positive results with the treatment. In the brain, probiotics reduce depressive symptoms (decreases in HAMA, GAD-7, and BDI-II scales), improving patients’ sleep quality and fatigue, enhancing cognitive subscales while slowing brain atrophy, and reducing IL-6 levels in the central areas, also modulating REM delta power to reduce high-frequency brain waves. Probiotics can also reduce cardiovascular risk factors, such as inflammation. Probiotics can also benefit the heart by decreasing TMAO, LDL-c, TG, CRP, MDA, TNF-α, IL-6, and urea levels, improving dyslipidemia and toxin profiles. Probiotics also increase HDL-c, ApoE, and insulin sensitivity, decreasing BMI, body fat, and the risk of developing chronic hyperglycemia while increasing lean mass. Besides, probiotic supplementation helped reduce toxic uremic toxins (serum urea) and sodium levels, bringing benefits to the kidneys, and improve energy/amino acid metabolism. Probiotics can also modulate and enhance kidney function due to decreased pro-inflammatory TGFβ-1 and TNF-α levels and RUNX2. Furthermore, enhanced gastrointestinal motility and diversity have been reported using specific bacteria. Although probiotics can bring several health benefits, there are still challenges regarding these supplements, such as dose, frequency, and pharmaceutical formula. Therefore, new studies are welcome to deepen the understanding of these microorganisms.
Catalpol: An Iridoid Glycoside With Potential in Combating Cancer Development and Progression—A Comprehensive Review Lucas Fornari Laurindo, Victória Dogani Rodrigues, Elen Landgraf Guiguer, Lívia Fornari Laurindo, Debora Aparecida Pires de Campos Zuccari, et al. Phytotherapy Research, 2025 Catalpol, a natural iridoid glycoside known for its anti‐proliferative effects, has been proposed as an anticancer compound. Catalpol targets critical processes involved in cancer cell progression, like malignant proliferation, apoptosis, and metastasis. Additionally, catalpol presents potent anti‐inflammatory and antioxidant properties crucial for cancer prevention and intervention. Due to the absence of clinical trials, this review investigates twelve studies, encompassing in vitro and animal trials from reputable databases, such as PubMed, with no time restrictions. Therefore, we covered evidence from catalpol's effects against several types of cancer, including breast, liver, colorectal, lung, gastric, bladder, and ovarian cancer, as well as osteosarcoma, and assessed various outcomes related to cell viability, apoptosis, migration, and modulation of molecular mechanisms by catalpol. Notably, catalpol induced cancer cell death via induction of mitochondrial apoptosis pathways, regulation of the expression of specific microRNAs, modulation of Sirt1, Kras, RACK1, PARP, PI3K/Akt, Bcl‐2, and STAT3/JAK2/Src signaling pathways, and inactivation of NF‐kB and Smad 2/3 signaling pathways. Furthermore, catalpol limits cancer metastasis due to modulation of critical metalloproteinases associated with cancer migration. Catalpol also synergizes with chemotherapeutic and adjuvant agents to induce cancer control, including regorafenib in liver cancer and chloroquine in gastric cancer, promoting increased anticancer action via upregulated cancer cell apoptosis, decreased proliferation, and inhibited angiogenesis via PI3K/p‐Akt/mTOR/NF‐κB, VEGF/VEGFR2, and Bax signaling pathways modulation. Catalpol derivatives also gained attention. Pyrazole‐, imidazole‐, and hydrolyzed‐based catalpol derivatives increase cancer cell apoptosis and death and decrease tumor angiogenesis through similar pathways. This review seeks to provide understanding of catalpol's anticancer effects, its mechanisms of action, and its potential as a therapeutic anticancer agent while advocating for future research conductance.
AdipoRon as a Novel Therapeutic Agent for Depression: A Comprehensive Review of Preclinical Evidence Lucas Fornari Laurindo, Victória Dogani Rodrigues, Rodrigo Haber Mellen, Rafael Santos de Argollo Haber, Vitor Engrácia Valenti, et al. Biomedicines, 2025 Background/Objectives: Depression is a mood disorder that causes persistent sadness and loss of interest, and its etiology involves a condition known as hypoadiponectinemia, which is prevalent in depressive individuals compared with healthy individuals and causes neuroinflammation. The use of intact adiponectin protein to target neuroinflammation in depressive moods is complex due to the difficulties associated with using the intact protein. AdipoRon, a synthetic oral adiponectin receptor agonist that targets the AdipoR1 and AdipoR2 receptors for adiponectin, has emerged in this context. Its most prominent effects include reduced inflammation and the attenuation of oxidative stress. To the best of our knowledge, no comprehensive review has addressed these results so far. To fill this literature gap, we present a comprehensive review examining the effectiveness of AdipoRon in treating depression. Methods: Only preclinical models are included due to the absence of clinical studies. Results: Analyzing the included studies shows that AdipoRon demonstrates contrasting effects against depression. However, most of the evidence underscores AdipoRon-based adiponectin replacement therapies as potential candidates for future treatment against this critical psychiatric condition due to their anti-neuroinflammatory potential, ultimately inhibiting several neuroinflammatory pathways. Conclusions: Future research endeavors must address several limitations due to the heterogeneity of the studies’ methodologies and results.
Targeting Muscle Regeneration with Small Extracellular Vesicles from Adipose Tissue-Derived Stem Cells—A Review Lucas Fornari Laurindo, Enzo Pereira de Lima, Adriano Cressoni Araújo, Victória Dogani Rodrigues, Jefferson Aparecido Dias, et al. Cells, 2025 Extracellular vesicles (EVs) are membrane-bound structures released by cells carrying diverse biomolecules involved in intercellular communication. Small EVs are abundant in body fluids, playing a key role in cell signaling. Their natural occurrence and therapeutic potential, especially in the context of muscular disorders, make them a significant area of research. Sarcopenia, characterized by progressive muscle fiber loss, represents a pathological state in which EVs could offer therapeutic benefits, reducing morbidity and mortality. Recent studies have proposed an interplay between adipose tissue (AT) and skeletal muscle regarding sarcopenia pathology. AT dysregulation, as seen in obesity, contributes to skeletal muscle loss in a multifactorial way. While AT-derived stem cell (ATDSC) small EVs have been implicated in musculoskeletal homeostasis, their precise action in muscle regeneration remains incompletely understood. In this context, ATDSC-derived small EVs can stimulate skeletal muscle regeneration through improved proliferation and migration of muscle cells, enhancement of muscular perfusion, improvement of tendon and nerve regeneration, stimulation of angiogenesis, and promotion of myogenic differentiation. However, they can also increase skeletal muscle loss. Notably, this is the first comprehensive review to systematically examine the role of ATDSC-derived small EVs in sarcopenia.
Unraveling the Metabolic Pathways Between Metabolic-Associated Fatty Liver Disease (MAFLD) and Sarcopenia Marina Ribas Losasso, Maria Luiza Cesto Parussolo, Antony Oliveira Silva, Rosa Direito, Karina Quesada, et al. International Journal of Molecular Sciences, 2025 Metabolic-Associated Fatty Liver Disease (MAFLD) is a public health concern that is constantly expanding, with a fast-growing prevalence, and it affects about a quarter of the world’s population. This condition is a significant risk factor for cardiovascular, hepatic, and oncologic diseases, such as hypertension, hepatoma, and atherosclerosis. Sarcopenia was long considered to be an aging-related syndrome, but today, it is acknowledged to be secondarily related to chronic diseases such as metabolic syndrome, cardiovascular conditions, and liver diseases, among other comorbidities associated with insulin resistance and chronic inflammation, besides inactivity and poor nutrition. The physiopathology involving MAFLD and sarcopenia has still not been solved. Inflammation, oxidative stress, mitochondrial dysfunction, and insulin resistance seem to be some of the keys to this relationship since this hormone target is mainly the skeletal muscle. This review aimed to comprehensively discuss the main metabolic and physiological pathways involved in these conditions. MAFLD and sarcopenia are interconnected by a complex network of pathophysiological mechanisms, such as insulin resistance, skeletal muscle tissue production capacity, chronic inflammatory state, oxidative stress, and mitochondrial dysfunction, which are the main contributors to this relationship. In addition, in a clinical analysis, patients with sarcopenia and MAFLD manifest more severe hepatitis fibrosis when compared to patients with only MAFLD. These patients, with both disorders, also present clinical improvement in their MAFLD when treated for sarcopenia, reinforcing the association between them. Lifestyle changes accompanied by non-pharmacological interventions, such as dietary therapy and increased physical activity, undoubtedly improve this scenario.
Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis Nathália Mendes Machado, Maria Vitória Barroso Oliveira, Karina Quesada, Jesselina Francisco dos Santos Haber, Ricardo José Tofano, et al. Pharmaceuticals, 2025 Background: Lipid-lowering therapies are an option for stabilizing lipid levels. Icosapent ethyl (IPE) is a highly purified formulation of eicosapentaenoic acid, which can reduce lipid action, improve plaque stabilization, reduce platelet aggregation, lower TG, and prevent cardiovascular events. IPE is frequently used with statins to manage elevated TG levels. However, the evidence on IPE as a lipid-lowering agent is limited, and no updated systematic review and meta-analysis have been published considering the recent advancements in the field and newly published studies. Therefore, we aim to fill this gap. Methods: We used the PRISMA guidelines and the PICO (Population, Intervention, Comparison, and Outcome) framework to conduct this review, aiming to answer the question, “Can IPE benefit patients at cardiovascular risk?” GRADE was used to evaluate evidence levels to adhere to the highest criteria. Results: Predominantly, the evaluated population presented TG levels between ≥135 mg/dL and 500 mg/dL and LDL-C levels between >40 mg/dL and ≤100 mg/dL. The included studies showed a reduction in TG and LDL-C and a decrease in cardiovascular events. It means that, according to our systematic review evidence analysis, IPE has been effective in lowering blood lipid levels, including TG, and reducing cardiovascular death and events, such as non-fatal stroke or hospitalization for unstable angina. However, it is worth noting that these results were primarily from patients undergoing statin therapy. According to our meta-analysis, IPE may not be considered a lipid-lowering drug, as limited action associated with its use was evident in the quantitative results. However, caution is necessary, as only two studies were suitable for inclusion due to the differing outcomes in the analyzed samples. Conclusions: Despite the quantitative synthesis, IPE possesses anti-inflammatory, anti-thrombotic, and anti-atherogenic properties, highly related to cardiovascular protection. Based on our included studies, IPE was considered a promising therapy for atherosclerotic cardiovascular disease in conjunction with other lipid-lowering therapies, particularly statins, for patients with extremely high TG levels. The limitations of the reviewed studies may include small sample sizes, varying outcomes, and a small duration of interventions. Future clinical trials with similar outcomes, sample sizes, and intervention durations must be designed, and updated meta-analyses must be published in the following years to fully assess the effects of IPE as a lipid-lowering and cardiovascular protector drug.
Development and Characterization of Mesembryanthemum crystallinum L. Extract-Loaded Phytosomes for Enhanced Delivery of Antioxidant Compounds I Fernandes, A Iglesias-Mejuto, JMP Coelho, R Direito, CP Reis Life 16 (4), 557 , 2026 2026
Artificial ovaries and the future of women's health: Shaping novel functions JPRL de Lima, RPF Abuna, MA Miglino, LB Arantes, LF Laurindo, ... Translational Research , 2026 2026
Catalpol: An Iridoid Glycoside With Potential in Combating Cancer Development and Progression—A Comprehensive Review LF Laurindo, VD Rodrigues, EL Guiguer, LF Laurindo, ... Phytotherapy Research 39 (10), 4950-4971 , 2025 2025 Citations: 5
Oral Salvia officinalis phenolics abolish mortality and mitigate inflammation in acute TNBS murine colitis R Direito, J Rocha, IA de Melo, M Gonçalves, MP Duarte, A Fernandes, ... Fitoterapia, 106870 , 2025 2025 Citations: 1
Bridging the gut microbiota and the brain, kidney, and cardiovascular health: The role of probiotics MR Lopes, R Direito, EL Guiguer, VCS Catharin, TLM Zutin, CJ Rubira, ... Probiotics and Antimicrobial Proteins, 1-25 , 2025 2025 Citations: 3
Advances in Understanding Long COVID: Pathophysiological Mechanisms and the Role of Omics Technologies in Biomarker Identification: MD da Silva et al. MD da Silva, TS da Silva, CG Mendes, MCM Valbão, AK Badu-Tawiah, ... Molecular Diagnosis & Therapy 29 (5), 617-636 , 2025 2025 Citations: 7
Phytosomal delivery enhances bioactivity of Hylocereus costaricensis phenolic extract R Direito, I Sousa, F Antunes, SM Barbalho, S Simões, MR Bronze, ... Frontiers in Nutrition 12, 1659572 , 2025 2025 Citations: 3
AdipoRon as a novel therapeutic agent for depression: a comprehensive review of preclinical evidence LF Laurindo, V Dogani Rodrigues, R Haber Mellen, RSA Haber, ... Biomedicines 13 (8), 1867 , 2025 2025 Citations: 4
Unraveling the metabolic pathways between metabolic-associated fatty liver disease (MAFLD) and sarcopenia MR Losasso, MLC Parussolo, A Oliveira Silva, R Direito, K Quesada, ... International journal of molecular sciences 26 (10), 4673 , 2025 2025 Citations: 15
Targeting Muscle Regeneration with Small Extracellular Vesicles from Adipose Tissue-Derived Stem Cells—A Review LF Laurindo, EP Lima, AC Araujo, V Dogani Rodrigues, JA Dias, ... Cells 14 (10), 683 , 2025 2025 Citations: 5
Assessing omega-3 therapy and its cardiovascular benefits: What about icosapent ethyl? A systematic review and meta-analysis NM Machado, MVB Oliveira, K Quesada, JFS Haber, R José Tofano, ... Pharmaceuticals 18 (4), 601 , 2025 2025 Citations: 5
Polyphenols, alkaloids, and terpenoids against neurodegeneration: evaluating the neuroprotective effects of phytocompounds through a comprehensive review of the current evidence EP de Lima, LF Laurindo, VCS Catharin, R Direito, M Tanaka, ... Metabolites 15 (2), 124 , 2025 2025 Citations: 85
Evaluating the effects of seed oils on lipid profile, inflammatory and oxidative markers, and glycemic control of diabetic and dyslipidemic patients: a systematic review of … L Fornari Laurindo, L Fornari Laurindo, V Dogani Rodrigues, ... Frontiers in Nutrition 12, 1502815 , 2025 2025 Citations: 9
Melatonin from plants: going beyond traditional central nervous system targeting—a comprehensive review of its unusual health benefits LF Laurindo, OAG Simili, AC Araújo, EL Guiguer, R Direito, VE Valenti, ... Biology 14 (2), 143 , 2025 2025 Citations: 5
EVALUATING THE EFFECTS OF SEED OILS ON LIPID PROFILE, INFLAMMATORY AND OXIDATIVE MARKERS, AND GLYCEMIC CONTROL OF DIABETIC AND DYSLIPIDEMIC PATIENTS: A SYSTEMATIC REVIEW OF … LL FORNARI, RV DOGANI, COJ DA SILVA, BB LEME, AA CRESSONI, ... FRONTIERS 12 , 2025 2025
Yanaguizawa Junior, JL; Dias, JA; et al LF Laurindo, OAG Simili, AC Araújo, EL Guiguer, R Direito, VE Valenti, ... Melatonin from Plants: Going Beyond Traditional Central Nervous System … , 2025 2025 Citations: 4
Isoorientin: Unveiling the hidden flavonoid's promise in combating cancer development and progression–A comprehensive review LF Laurindo, KT Pomini, EP de Lima, LF Laurindo, VD Rodrigues, ... Life sciences 360, 123280 , 2025 2025 Citations: 15
Targeting AMPK with Irisin: Implications for metabolic disorders, cardiovascular health, and inflammatory conditions—A systematic review LF Laurindo, VD Rodrigues, LF Laurindo, LMA Cherain, EP de Lima, ... Life Sciences 360, 123230 , 2025 2025 Citations: 23
Health benefits of acerola (Malpighia spp) and its by-products: A comprehensive review of nutrient-rich composition, pharmacological potential, and industrial applications LF Laurindo, LN Takeda, NM Machado, AMMB Otoboni, ... Food Bioscience 62, 105422 , 2024 2024 Citations: 10
The therapeutic potential of bee venom-derived Apamin and Melittin conjugates in cancer treatment: A systematic review LF Laurindo, EP de Lima, LF Laurindo, VD Rodrigues, EFB Chagas, ... Pharmacological research 209, 107430 , 2024 2024 Citations: 31
MOST CITED SCHOLAR PUBLICATIONS
Anthocyanins: Metabolic digestion, bioavailability, therapeutic effects, current pharmaceutical/industrial use, and innovation potential H Ayvaz, T Cabaroglu, A Akyildiz, CU Pala, R Temizkan, E Ağçam, ... Antioxidants 12 (1), 48 , 2022 2022 Citations: 184
Anti-inflammatory, antioxidant, and other health effects of dragon fruit and potential delivery systems for its bioactive compounds DF Nishikito, ACA Borges, LF Laurindo, AMMB Otoboni, R Direito, ... Pharmaceutics 15 (1), 159 , 2023 2023 Citations: 156
Ginkgo biloba in the Aging Process: A Narrative Review SM Barbalho, R Direito, LF Laurindo, LT Marton, EL Guiguer, RA Goulart, ... Antioxidants 11 (3), 525 , 2022 2022 Citations: 128
Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri : A Systematic Review Focused on Inflammation, Oxidative Stress … LJ Valotto Neto, M Reverete de Araujo, RC Moretti Junior, ... Antioxidants 13 (4), 393 , 2024 2024 Citations: 117
Protective effects of hydroxytyrosol-supplemented refined olive oil in animal models of acute inflammation and rheumatoid arthritis S Silva, B Sepodes, J Rocha, R Direito, A Fernandes, D Brites, M Freitas, ... The Journal of nutritional biochemistry 26 (4), 360-368 , 2015 2015 Citations: 113
Curcumin-based nanomedicines in the treatment of inflammatory and immunomodulated diseases: an evidence-based comprehensive review LF Laurindo, GM de Carvalho, B de Oliveira Zanuso, ME Figueira, ... Pharmaceutics 15 (1), 229 , 2023 2023 Citations: 112
Investigating the neuroprotective and cognitive-enhancing effects of Bacopa monnieri: a systematic review focused on inflammation, oxidative stress, mitochondrial dysfunction … LJV Neto, MR de Araujo, RCM Junior, NM Machado, RK Joshi, ... Antioxidants 13 (4), 393 , 2024 2024 Citations: 99
Polyphenols, alkaloids, and terpenoids against neurodegeneration: evaluating the neuroprotective effects of phytocompounds through a comprehensive review of the current evidence EP de Lima, LF Laurindo, VCS Catharin, R Direito, M Tanaka, ... Metabolites 15 (2), 124 , 2025 2025 Citations: 85
Phenolic compounds impact on rheumatoid arthritis, inflammatory bowel disease and microbiota modulation R Direito, J Rocha, B Sepodes, M Eduardo-Figueira Pharmaceutics 13 (2), 145 , 2021 2021 Citations: 76
From Diospyros kaki L. (Persimmon) Phytochemical Profile and Health Impact to New Product Perspectives and Waste Valorization R Direito, J Rocha, B Sepodes, M Eduardo-Figueira Nutrients 13 (9), 3283 , 2021 2021 Citations: 75
Phytosomes with Persimmon ( Diospyros kaki L.) Extract: Preparation and Preliminary Demonstration of In Vivo Tolerability R Direito, C Reis, L Roque, M Gonçalves, A Sanches-Silva, MM Gaspar, ... Pharmaceutics 11 (6), 296 , 2019 2019 Citations: 75
Ginkgo biloba : A Leaf of Hope in the Fight against Alzheimer’s Dementia: Clinical Trial Systematic Review GLO Pagotto, LMO Santos, N Osman, CB Lamas, LF Laurindo, KT Pomini, ... Antioxidants 13 (6), 651 , 2024 2024 Citations: 69
Chemical characterization of a red raspberry fruit extract and evaluation of its pharmacological effects in experimental models of acute inflammation and collagen-induced arthritis ME Figueira, MB Câmara, R Direito, J Rocha, AT Serra, CMM Duarte, ... Food & function 5 (12), 3241-3251 , 2014 2014 Citations: 66
Metabolic-associated fatty liver disease: the influence of oxidative stress, inflammation, mitochondrial dysfunctions, and the role of polyphenols RB Tauil, PT Golono, EP de Lima, R de Alvares Goulart, EL Guiguer, ... Pharmaceuticals 17 (10), 1354 , 2024 2024 Citations: 61
Protective effects of a blueberry extract in acute inflammation and collagen-induced arthritis in the rat ME Figueira, M Oliveira, R Direito, J Rocha, P Alves, AT Serra, C Duarte, ... Biomedicine & Pharmacotherapy 83, 1191-1202 , 2016 2016 Citations: 59
Dyospiros kaki phenolics inhibit colitis and colon cancer cell proliferation, but not gelatinase activities R Direito, A Lima, J Rocha, RB Ferreira, J Mota, P Rebelo, A Fernandes, ... The Journal of Nutritional Biochemistry 46, 100-108 , 2017 2017 Citations: 58
Combination of hyaluronic acid and PLGA particles as hybrid systems for viscosupplementation in osteoarthritis AH Mota, R Direito, MP Carrasco, P Rijo, L Ascensão, AS Viana, J Rocha, ... International journal of pharmaceutics 559, 13-22 , 2019 2019 Citations: 49
Plant-derived bioactive compounds: exploring neuroprotective, metabolic, and hepatoprotective effects for health promotion and disease prevention R Direito, SM Barbalho, B Sepodes, ME Figueira Pharmaceutics 16 (5), 577 , 2024 2024 Citations: 35
Anti-inflammatory Effects of Persimmon ( Diospyros kaki L.) in Experimental Rodent Rheumatoid Arthritis R Direito, J Rocha, AT Serra, A Fernandes, M Freitas, E Fernandes, ... Journal of dietary supplements 17 (6), 663-683 , 2020 2020 Citations: 34
Medicinal plants, phytochemicals and regulation of the NLRP3 inflammasome in inflammatory bowel diseases: a comprehensive review R Direito, SM Barbalho, ME Figueira, G Minniti, GM de Carvalho, ... Metabolites 13 (6), 728 , 2023 2023 Citations: 33